Interestingly, NTRK2 inhibitors such as entrectinib significantly reduced the proliferation of glioma cells in vitro. BDNF-NTRK2 signaling axis is a prime example of how glioma cells reinvent neural plasticity during tumor progression (Table 1). Here, NTRK2 is linked to central nervous system cancer.